I realize that the events of 2001 have seriously damaged our credibility with many of our constituents, including cancer patients, oncologists, and you, our investors.

We view the meeting with the FDA as very productive.

There was no material information available to me at that time.

I feel great remorse, but I do not feel bitter.

We now know that we could and should have done a better job in putting together our application package, ... We let patients down, and for that, I am truly sorry.